预约演示

更新于：2026-02-07

Psilocybin

裸盖菇素

更新于：2026-02-07

概要

基本信息

药物类型

小分子化药

别名

ELE-PSILO、ELE-Psilo+、fast-releasing psilocybin oral formulation(Cybin)

+ [31]

靶点

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor

作用方式

拮抗剂、激动剂

作用机制

5-HT1A receptor拮抗剂(5-羟色胺1A受体拮抗剂)、5-HT2A receptor激动剂(5-羟色胺2A受体激动剂)、5-HT2C receptor激动剂(5-羟色胺2C受体激动剂)

治疗领域

神经系统疾病肿瘤免疫系统疾病+ [6]

在研适应症

重度抑郁症难治性抑郁症腰痛+ [45]

非在研适应症

遗忘躯体变形障碍脆性X综合征+ [3]

原研机构-

在研机构

Compass Pathways Plc

Filament Health Corp.APeT Holding B.V.

+ [33]

非在研机构

KGK Science, Inc.

The University of New Mexico

Beckley Psytech Ltd.

+ [2]

权益机构

Revive Therapeutics Ltd.

Psyence Biomedical Ltd.

Psirenity

+ [17]

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、创新许可和获取途径 (英国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS号520-52-5

关联

295

项与裸盖菇素相关的临床试验

NCT06005662

/ Suspended临床2期IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

开始日期2027-04-01

申办/合作机构

The Johns Hopkins University

NCT07306364

/ Not yet recruiting临床2期IIT

Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes

The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.

开始日期2026-06-01

申办/合作机构

Yale University

[+1]

NCT07226232

/ Not yet recruiting临床3期IIT

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

开始日期2026-06-01

申办/合作机构

VA Office of Research and Development

100 项与裸盖菇素相关的临床结果

登录后查看更多信息

100 项与裸盖菇素相关的转化医学

登录后查看更多信息

100 项与裸盖菇素相关的专利（医药）

登录后查看更多信息

2,353

项与裸盖菇素相关的文献（医药）

2026-05-01·NEUROPHARMACOLOGY

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms

Article

作者: Bengtsson, Niklas ; Lucente, Erika ; Domi, Ana ; Smedler, Erik ; Adermark, Louise ; Cadeddu, Davide

Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neurotransmission in the prefrontal cortex (PFC). Slice electrophysiological whole-cell and field potential recordings were conducted in the rat prelimbic cortex during bath application of psilocin. We observed a sex-independent long-term synaptic depression (LTD) of presynaptic origin. This effect was independent of 5-HT_2A and metabotropic glutamatergic receptor group 2 and mediated through enhanced GABAergic tone. The effect was partially inhibited by 5-HT_1A receptor antagonist and completely blocked in slices pre-treated with the neuronal receptor tyrosine kinase 2 (TrkB) receptor antagonist ANA-12. These findings suggest that psilocin exerts a complex modulatory influence on excitatory neurotransmission in the prelimbic PFC, involving GABAergic and serotonergic interactions, and producing sustained alterations in synaptic activity that persist beyond drug exposure. Psilocin-induced LTD, independent of 5-HT_2A receptor activation, may be associated with the reduced prefrontal connectivity reported in humans after psilocin administration and could have implications for cognitive function.

2026-05-01·JOURNAL OF AFFECTIVE DISORDERS

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Article

作者: Sergent, Felix ; Luquiens, Amandine ; Mura, Thibault ; Belahda, Dahbia ; Igounenc, Noé ; Graux, Carine ; Garcia, Maria Garcia ; Serrand, Chris

BACKGROUND:

Psilocybin-assisted psychotherapy shows promise in alcohol use disorder (AUD), but therapeutic mechanisms remain poorly understood. Previous qualitative studies have described potential processes such as gaining insights, altered self-perception, connectedness, and changes in coping, yet findings remain limited and inconsistent in AUD, and little is known about early markers of therapeutic response.

METHODS:

We conducted a mixed quantitative-qualitative analysis of first integration sessions in the Psilocybin Alcohol Depression (PAD) randomized controlled trial. Only participants randomized to the 25 mg psilocybin group were included in this analysis. Recently detoxified patients with AUD and persisting depressive symptoms underwent semi-structured integration interviews the day after dosing. Transcripts were analyzed with IRaMuTeQ software using the Reinart descending hierarchical classification. Associations with abstinence at 3 months were examined.

RESULTS:

Twenty participants were included (55% male, median age 49); 55% were abstinent at 3 months. The corpus comprised 127,760 words, with 88% classified into two stable classes. Class 1 (44% of text segments) described sensory and emotional aspects of the psychedelic experience (physical sensations, visual phenomena, emotions, setting) and was predominantly elicited by non-responders. Class 2 (56%) reflected active cognitive processes and inner dialogue, including cognitive restructuring, distancing from habitual patterns, commitment to change, and work on pre-elicited intentions related to alcohol. Abstinence at 3 months was significantly associated with references to family connections, pleasant emotions, adaptive processing of fear, and revisiting alcohol-related triggers with new coping strategies, while non-abstinence was associated with negative emotions, physical pain, disappointment, and suppressive coping.

CONCLUSIONS:

Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.

2026-05-01·JOURNAL OF AFFECTIVE DISORDERS

Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts

Article

作者: Carruthers, Sean P ; Mills, Laura ; Rossell, Susan L

Psilocybin has been reported to decrease depression symptoms among individuals with bipolar disorder (BD), but has also been associated with reports of mania, psychosis and increased depression. With increasing recreational use of psilocybin, and the potential for psilocybin to be used as a treatment for depression, a better understanding of the risks and benefits of this psychedelic among individuals with BD is warranted. Individuals have used social media sites like Reddit to share their experiences with psilocybin, providing an opportunity to understand a range of perspectives and experiences. The current study aimed to further explore psilocybin experiences as shared on Reddit, with a focus on posts related to BD. A thematic analysis of Reddit posts and comments was undertaken, with a focus on those identified with search terms, "bipolar" AND "psilocybin" OR "mushrooms". A total of 354 comments with a first-hand psilocybin experience were identified and included in the thematic analysis which revealed four core themes: (1) mania, (2) depression, (3) mixed experiences, and (4) broader perspectives. Psilocybin was reported to have benefits in some comments, including reduced depression symptoms and shifts in perspective about oneself and/or the world. However, reports of increased or new mania and psychosis symptoms were also reported, as well as increased depression. While psilocybin may benefit some individuals with BD, there may be potential for increased mania, psychosis and depression symptoms. Understanding the factors that contribute positive and negative outcomes among individuals with BD will be important in future research.

1,206

项与裸盖菇素相关的新闻（医药）

2026-02-04

·EINPresswire

Intrinsic Interventions Launches VistaFlow Specialty Street Drug Cup to Detect Emerging High-Risk Substances

Specialty Street Drug Cup Released That Instantly Detects Emerging Street and Prescription Drugs of Abuse Street drugs today look very different than they did even a few years ago. This cup was built specifically for what our clients are encountering in the field.” — Kelly Burdge SARASOTA, FL, UNITED STATES, February 4, 2026 / EINPresswire.com / -- Intrinsic Interventions, an industry-leading provider of point-of-care, onsite drug screening devices with nearly two decades of experience, announces the release of its VistaFlow Specialty Street Drug Cup . This new 12-panel device instantly detects emerging and high-risk street and prescription drugs that continue to impact public safety, corrections, treatment programs, and community services nationwide. The Specialty Street Drug Cup expands the VistaFlow product line to address substances increasingly encountered by criminal justice agencies, social service organizations, treatment providers, and compliance professionals. As patterns of drug misuse evolve beyond traditional opioids and stimulants, Intrinsic Interventions developed this device to help professionals identify substances often not detected by traditional instant drug screen panels, but which carry significant health and safety risks. “Street drugs today look very different than they did even a few years ago,” a company spokesperson said. “This cup was built specifically for what our clients are encountering in the field—substances that complicate supervision, treatment, and public safety efforts.” These substances reflect a cross-section of synthetic opioids, dissociatives, hallucinogens, designer drugs, and adulterants increasingly found in street-level drug abuse. The VistaFlow Specialty Street Drug Cup detects the following 12 substances: • Fentanyl • Nitazenes (synthetic opioid) • Tianeptine (“gas station heroin”) • Xylazine (“tranq”) • Psilocybin (“magic mushrooms”) • 3,4-Methylenedioxyprovalerone (MDPV – bath salts) • Kratom • Lysergic Acid Diethylamide (LSD) • N,N-Dimethyltryptamine (DMT) • Gabapentin • Ketamine • Synthetic Marijuana (K2/Spice) The VistaFlow Specialty Street Drug Cup also includes three adulteration markers—pH, oxidants, and creatinine—key components of urinary specimen validity testing (SVT) used to ensure sample integrity by detecting adulteration and dilution. Impact and prevalence driving demand According to national public health and law enforcement reporting, fentanyl and fentanyl-analog contamination remains a leading contributor to overdose deaths, often appearing in non-opioid drugs without the user’s knowledge. Nitazenes, a newer class of synthetic opioids, have emerged as potent fentanyl alternatives, raising concern among toxicologists and first responders due to their extreme strength and detection challenges. Xylazine, a non-opioid veterinary sedative, has become a frequent adulterant in illicit drug supplies, complicating overdose response and treatment outcomes. Meanwhile, substances such as gabapentin and tianeptine are increasingly misused due to their availability and psychoactive effects, particularly within correctional and supervision settings. Hallucinogens including LSD, psilocybin, and DMT continue to appear in community and street drug markets, often perceived as low risk despite documented cognitive and behavioral effects. Ketamine misuse has expanded beyond medical contexts, while synthetic marijuana products remain unpredictable due to constantly changing chemical formulations. Emerging stimulant-like compounds such as MDPV and plant-derived substances like kratom further complicate monitoring efforts, especially in environments where polysubstance use is common. “Many of these substances are not captured by traditional test panels,” the spokesperson said. “Yet they are increasingly present in the populations our clients serve. This product was designed to close that gap.” Built for professional use The VistaFlow Specialty Street Drug Cup is designed for ease of use in professional environments, delivering rapid results that support timely decision-making. It is suited for corrections departments, probation and parole programs, treatment providers, social service agencies, and organizations requiring consistent, defensible screening tools. Intrinsic Interventions has served the drug testing industry since 2007, providing instant screening products and access to certified laboratory confirmation services when required. Programs using VistaFlow products can transition seamlessly from onsite screening to GC/MS or LC-MS/MS confirmation through national laboratory partners, supporting compliance and evidentiary standards. VistaFlow products are distributed directly through Intrinsic Interventions and authorized channels, helping ensure product integrity and proper use. This controlled distribution approach differentiates VistaFlow from consumer-grade testing products and supports the company’s emphasis on accuracy, reliability, and customer support. Availability Now available through Intrinsic Interventions. Additional product information and ordering details are available at MyVistaFlow.com or by contacting customer support at (866) 210-2272. About Intrinsic Interventions Founded in 2007, Intrinsic Interventions provides professional drug testing products and services through its VistaFlow brand. The company supports criminal justice agencies, social service organizations, corrections departments, treatment programs, and workplaces with reliable screening tools and confirmation services designed to meet modern drug detection challenges. Kelly Burdge Intrinsic Interventions +1 866-210-2272 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2026-02-03

·Target Tracker

CNS领域药物研发进展（2025年Q4至今）

本报告基于对2025年第4季度至2026年1月份全球中枢神经系统（CNS）领域关键研发进展的系统性梳理，具体包含5个适应症领域，分别为疼痛、抑郁、癫痫、帕金森病（PD）及阿尔茨海默病（AD）。旨在跟踪行业趋势，并为产业决策者，研发人员及投资者提供前瞻视角。分析表明，CNS药物研发已进入一个由 “疾病修饰”、“精准分层”和“技术平台化”三大趋势引领的新时代。疾病疗法开发正从对症控制转向根源干预，从广谱用药转向生物标志物定义的细分人群，从单一分子竞争转向跨疾病技术平台的角逐。报告识别出非阿片类神经病理性疼痛治疗、快速起效抗抑郁新机制、基因/细胞疗法在单基因疾病中的应用、神经免疫调节及高效脑靶向递送技术等核心机遇。然而，科学机制复杂性、血脑屏障瓶颈、高昂开发成本与严峻支付压力构成主要挑战。建议大型药企应通过战略合作与并购，聚焦平台技术整合与后期资产引进；生物科技公司需深耕差异化技术或精准患者细分市场，构建竞争壁垒；投资者应关注具备临床验证数据的技术平台公司及采用创新临床试验设计的标的。后续我们也将基于本次报告的分析框架，持续关注CNS领域的新平台化技术，新靶点，新的商业模式。引言：站在范式迁移的临界点中枢神经系统疾病是全球范围内致残与造成社会经济负担的首要因素之一。传统上，该领域药物研发因血脑屏障阻隔、疾病机制复杂、动物模型预测性有限及临床终点主观性强而步履维艰，长期以症状缓解为主要目标。然而，2025年第四季度以来密集公布的一系列临床、监管及商业动态，清晰标志着一个转折点的到来。从Tonix的纤维肌痛新药Tonnya™凭借全新作用机制获批上市，到罗氏利用Brainshuttle™技术使抗淀粉样蛋白抗体Trontinemab实现“超快速”斑块清除；从礼来为强化神经退行性疾病管线收购Ventyx Biosciences，到Encoded Therapeutics与Stoke Therapeutics的基因靶向疗法在难治性癫痫中获得突破性认定——这些事件并非孤立，而是共同勾勒出一幅行业底层逻辑正在重构的图景。本报告将穿透现象，剖析驱动这些进展的深层范式转变，评估由此孕育的战略机遇，并为不同市场参与者绘制导航未来的行动路径。第一部分：分疾病领域进展深度剖析与范式转变信号 1.1 疼痛管理：超越阿片类，走向机制细分与疾病修饰关键进展：Tonix的Tonnya™（环苯扎林舌下片）获批成为15年来首款新机制纤维肌痛（FM）疗法，其通过调节睡眠结构起效，在RESILIENT III期试验中显著改善疼痛、疲劳与功能。Dogwood的Nav1.7抑制剂Halneuron在化疗诱导神经病理性疼痛（CINP）IIb期获积极结果。Pacira的基因疗法PCRX-201在骨关节炎（OA）疼痛中显示出镇痛与潜在疾病修饰的双重证据。范式转变体现：从“镇痛”到“治痛”：新药开发不再局限于阻断痛觉信号，而是干预疼痛维持的深层病理生理机制，如中枢敏化（Tonnya™）、特定离子通道功能（Halneuron）、神经免疫与关节退变（PCRX-201）。从“广谱”到“精准”：针对FM、CINP、OA等不同病因的精细化治疗策略取代了非特异性镇痛药。技术平台化：基因疗法（PCRX-201）、蛋白降解剂（Cullgen的泛TRK降解剂）等新兴技术模态开始应用于疼痛领域。 1.2 抑郁症：追求快速起效与根本突破，迷幻剂科学化与机制创新并行关键进展：Compass Pathways推进合成裸盖菇素COMP360在难治性抑郁症（TRD）的商业化准备。AbbVie收购Gilgamesh及其短效致幻剂bretisilocin。GH Research的吸入式美布芬汀GH001在IIb期显示中位11分钟精神活性体验和快速抗抑郁疗效。Alto Neuroscience的复方药ALTO-207（普拉克索+昂丹司琼）获关键方法专利。Artelo的FABP5抑制剂临床前研究支持其通过内源性大麻素系统起作用。范式转变体现：从“延迟起效”到“快速干预”：以5-HT2A受体为靶点的迷幻剂类疗法（COMP360， bretisilocin， GH001）及新型给药途径（吸入、鼻喷）旨在实现数小时甚至数十分钟内起效，应对重症患者紧急需求。从“单胺假说”到“神经可塑性与环路调节”：迷幻剂、谷氨酸系统调节剂（虽Neurocrine的NR2B拮抗剂受挫，但氯胺酮已验证）、内源性大麻素系统调节剂等，探索超越单胺能神经递质的新机制。老药新用的智慧创新：ALTO-207通过复方设计克服剂量限制性副作用，是优化已知有效机制的典范。 1.3 癫痫：从控制发作到修正疾病，基因治疗迎来高光时刻关键进展：Encoded Therapeutics的AAV基因疗法ETX101与Stoke/Biogen的反义寡核苷酸（ASO）zorevunersen均针对Dravet综合征的SCN1A基因，获突破性疗法认定，并显示改善神经发育的潜力。UCB的芬氟拉明成功扩展至CDKL5缺乏症。Xenon的KV7开放剂Azetukalner长期数据优异，III期结果待出。范式转变体现：从“对症”到“对因”：对于单基因遗传的发育性癫痫性脑病（DEE），基因疗法与ASO旨在纠正根本的遗传缺陷，目标是“治愈”或显著改变疾病进程。治疗目标的升级：终点从“减少发作频率”扩展到“改善认知、行为及生活质量”，真正追求神经发育获益。精准分型治疗：针对Dravet、CDKL5、Lennox-Gastaut等特定综合征的药物开发成为主流，推动伴随诊断发展。 1.4 帕金森病：多路径围攻疾病修饰，细胞疗法与靶向病理进入关键期关键进展：靶向α-突触核蛋白（α-syn）的疗法中，Modag的anle138b（与Teva合作）和ACImmune的疫苗ACI-7104.056取得临床进展。细胞疗法方面，Racthera的iPS细胞衍生疗法在日本提交上市申请，Aspen和BlueRock的疗法进入后期临床。针对GBA1突变的BIAL的pariceract在II期试验中。礼来收购Ventyx获得其NLRP3抑制剂VTX3232，其在早期PD中显示抗炎与症状改善效果。范式转变体现：疾病修饰成为绝对核心：所有前沿探索均明确以延缓或阻止疾病进展为目标，而非仅补充多巴胺。干预策略多元化：同时涵盖清除病理蛋白（α-syn）、细胞替代、调节神经炎症（NLRP3）、修复细胞功能（GCase激活、线粒体保护）等多条路径，形成“组合拳”趋势。平台技术竞争：iPS细胞培养分化技术成为细胞疗法的核心平台，其成熟度决定了产品成败。 1.5 阿尔茨海默病：后淀粉样蛋白时代的深水区竞争，递送技术决定成败关键进展：罗氏的Trontinemab利用Brainshuttle™技术，在早期试验中实现28周内>90%患者淀粉样蛋白清除，且ARIA风险低。Eisai/Biogen积极推动Leqembi皮下制剂，拓展家庭治疗。Eisai的抗tau抗体etalanetug显示降低tau生物标志物。Cognition的Sigma-2调节剂CT1812基于p-tau217分层推进III期。ProMIS的PMN310声称特异性靶向Aβ寡聚体。范式转变体现：递送效率成为瓶颈与突破口：大分子药物，尤其是抗体，其脑内暴露量直接决定疗效与安全性。高效、安全的脑靶向递送技术（如Brainshuttle™）从“锦上添花”变为“生死攸关”。联合治疗与精准分层成为必然：在Aβ基础上，联合tau、抗炎等靶点，并利用血浆生物标志物（p-tau217， APOE基因型）筛选最可能应答人群，是提升疗效和风险获益比的必由之路。治疗关口极致前移：临床试验越来越多地聚焦前驱期甚至无症状的淀粉样蛋白阳性人群，追求预防性干预。第二部分：综合趋势总结——三大根本性范式转移基于以上分析，全球CNS药物研发正经历以下相互关联的根本性范式转移：范式转移一：治疗目标从“症状控制”转向“疾病修饰”乃至“根源干预”。不再满足于暂时缓解症状，而是旨在延缓、阻止或逆转疾病的核心病理进程。PD中的α-syn靶向药和细胞疗法、AD中的Aβ/tau清除疗法、癫痫中的基因疗法（旨在纠正病因）、OA疼痛中的关节保护疗法。重新定义临床终点（需影像学、生物标志物等客观证据），拉长研发周期，但成功后产品生命周期和价值巨大。范式转移二：研发策略从“广谱适用”转向“生物标志物驱动的精准分层”。承认疾病的巨大异质性，利用基因组、蛋白组、影像组等信息，识别最可能对特定疗法应答的患者亚群。Cognition的CT1812在AD中基于p-tau217分层、BIAL的pariceract专攻GBA1突变PD、未来迷幻剂疗法可能基于脑连接组特征选择患者。提高临床试验成功率，实现更优风险获益比，催生伴随诊断市场，推动个性化医疗。范式转移三：竞争优势从“单一分子实体”转向“可扩展的技术平台”。核心竞争力不再仅是某个靶点的先发优势，而是能够跨疾病、跨靶点应用的技术引擎。罗氏的Brainshuttle™（可搭载不同抗体）、iPS细胞重编程与分化平台（应用于PD、眼科等）、PROTAC蛋白降解技术平台（可靶向不同蛋白）、基因编辑/递送平台。构建更高的竞争壁垒，平台型公司估值逻辑改变，Big Pharma通过收购平台快速布局多个领域。第三部分：机会-挑战矩阵分析与战略路径 3.1 未来3-5年高潜力机会评估 1. 神经病理性疼痛该领域的突破性机会在于开发非阿片类、针对特定机制的高选择性疗法。具体包括：高选择性Nav1.7/1.8钠通道抑制剂、靶向Kv7等钾通道的基因疗法，以及作用于外周系统的新靶点（如AAK1抑制剂）。其科学可行性高，相关靶点机制明确且得到遗传学充分验证。然而，临床开发风险中高，主要挑战在于复杂疼痛动物模型的预测性有限，且以患者主观报告为主要终点的临床试验波动性大。当前竞争日趋激烈，但通过聚焦差异化给药途径或特定适应症（如化疗诱导型神经病理性疼痛），仍存在显著机会。该市场潜力巨大，达百亿美金级别，核心价值在于替代现有阿片类药物及疗效不足的传统疗法。战略路径建议：生物科技公司可专注于具有全新机制或优越药代动力学特性的分子进行自主研发；而大型制药企业则应重点通过许可引进或并购，获取已进入临床II期验证阶段的成熟资产。 2. 快速起效抗抑郁该领域的突破解决难治性抑郁症（TRD）未满足需求的关键在于追求快速起效。主要技术方向分为两类：一是短效且副作用可控的迷幻剂类药物（5-HT2A受体调节剂），二是作用于谷氨酸能或内源性大麻素系统等新型快速起效机制。其科学可行性为中等至高，迷幻剂的疗效已获初步临床验证，但长期安全性尚需更多数据；新机制的生物学基础仍需进一步夯实。该领域临床开发风险高，主要体现在监管路径新颖、精神活性物质面临严格管控，以及临床试验中强大的安慰剂效应。竞争格局上，迷幻剂领域已有Compass Pathways等先发者领先，但下一代设计更优的化合物（如bretisilocin）正快速追赶。潜在市场规模巨大，尤其在难治性抑郁症领域。战略上，建议通过合作开发模式，与拥有精神科临床专长及特殊药品分销渠道的企业结盟；对于投资者而言，应重点投资那些具备独特给药系统（如吸入制剂）或拥有专利分子设计能力的平台型公司。 3. 单基因CNS疾病解决难针对由单基因缺陷引起的神经系统疾病（如Dravet综合征、雷特综合征、SMA及特定FTD/ALS亚型），基因疗法（AAV载体）与反义寡核苷酸疗法代表了根治性或疾病修饰性的未来。其科学可行性极高，因为单基因缺陷的因果关系明确。临床开发风险中高，核心挑战在于递送效率、免疫原性以及治疗效果的长期稳定性。目前该领域尚属蓝海，但技术、生产工艺和临床开发门槛极高，形成了强大的进入壁垒。市场规模为中到高，遵循孤儿药定价逻辑。战略性建议是：进行平台投资或并购，优先收购拥有高效且安全的中枢神经系统递送载体技术的公司；同时，与专科诊断公司及患者倡导组织建立紧密联盟，以精准定位患者并加速临床开发。 4. 神经免疫调节神经炎症是众多CNS疾病的共同病理环节。机会点在于开发小分子NLRP3炎症小体抑制剂、抗炎细胞因子调节剂（如可溶性TNF中和剂）以及针对小胶质细胞的特异性疗法。其科学可行性中等，炎症的病理角色已获公认，但具体的因果关联及最佳治疗干预窗口仍需在人体中进一步厘清。临床开发风险中高，成功的关键在于在患者群体中验证所选生物标志物的变化能否转化为明确的临床获益。当前此为新兴热点，多家公司均有布局，竞争差异主要体现在靶点选择和适应症聚焦上。潜在市场规模大，尤其在阿尔茨海默病、帕金森病、肌萎缩侧索硬化等重大适应症中。战略上，企业可自主研发能够穿透血脑屏障的靶向化合物，或通过引进已完成初步临床概念验证的资产，以降低早期研发风险。 5. 高效脑靶向递送这是赋能整个CNS药物研发的底层关键技术平台。前沿方向包括：用于抗体/大分子药物的受体介导的转胞吞技术、新型核酸递送载体，以及聚焦超声暂时性开放血脑屏障的物理方法。其科学可行性高，部分技术已获得临床概念验证。开发风险中等，主要关注长期安全性、免疫原性和复杂的生产工艺。该领域已形成高技术壁垒，少数经过验证的领先平台（如罗氏的Brainshuttle™）价值凸显。其市场潜力极佳，作为一个平台可赋能和提升多个治疗管线的价值。战略建议是：寻求战略合作，与拥有领先平台技术的公司达成广泛的合作或期权协议；对于资源充足的大型药企，则可考虑投入资源内部平台建设，或通过并购直接获取核心技术与团队。 3.2 核心挑战与风险研判及应对思路科学机制复杂性：多数CNS疾病为多基因、多因素疾病，动物模型预测性差，靶点与临床表型关联不确定。加大对人源化模型（类器官、芯片器官）的投入；加强人类遗传学与多组学研究，寻找高置信度靶点；采用“快速学试错”的临床前到临床转化策略。血脑屏障（BBB）瓶颈：限制>98%的小分子和几乎所有大分子入脑。将BBB穿透性作为先导化合物优化的核心指标；积极布局或引进脑靶向递送平台技术（RMT、载体、物理方法）；探索外周作用靶点（如肠-脑轴、外周免疫）。临床开发与监管门槛：主观终点（如疼痛评分、抑郁量表）波动大；疾病修饰需要长期、昂贵的试验；监管机构对新型疗法（基因治疗、迷幻剂）审慎。采用客观生物标志物（影像、液体活检）作为次要终点或富集工具；与监管机构早期、频繁沟通，寻求创新试验设计（如适应性设计、主协议试验）的认可；积极参与监管科学讨论，帮助制定新框架。支付与市场准入压力：基因疗法、细胞疗法、长期生物制剂定价高昂；疾病修饰疗法的长期价值需真实世界数据证明；医保支付方压力增大。早期开展健康经济学研究，证明疗法在减少整体医疗成本、提升生产力方面的价值；探索风险共担、按疗效付费等创新支付协议；清晰定义治疗获益最大的患者群体，实现精准定价与准入。第四部分：结论与差异化战略建议总体结论：全球CNS药物研发已步入一个技术驱动、精准导向、平台制胜的新周期。未来的竞争将是三维的：靶点生物学深度、递送/平台技术高度、以及临床开发策略精度。单纯跟随式（me-too）的分子开发价值将迅速衰减，而拥有突破性技术平台、深度疾病生物学见解或独特临床开发能力的组织将掌握主导权。差异化战略建议：对于大型制药企业（Big Pharma）：战略定位：成为平台整合者与后期资产赋能者。利用强大的资本、全球开发与商业化网络，系统性扫描并收购或深度合作拥有颠覆性技术平台（脑递送、基因编辑、细胞疗法平台）的中小型公司。管线构建：内部研发应聚焦于经过遗传学充分验证的靶点，并积极应用外部引进的先进递送技术。外部BD重点应放在临床II期概念验证（PoC）成功后的资产，以降低风险，加速上市。应对支付：牵头与支付方就高价值创新疗法（如疾病修饰疗法）建立新的价值评估与支付框架，担当行业责任。对于中小型生物科技公司（Biotech）：战略定位：成为细分领域的颠覆者或技术平台的领导者。避免在拥挤的赛道上进行分子层面的微小创新。聚焦策略：要么在特定疾病领域（如一种罕见癫痫）做到生物学理解最深、疗法最前沿；要么将一个核心技术平台（如一种新型AAV衣壳、一种PROTAC连接子）做到全球最优，并寻求与多家药企合作验证。临床开发：善于利用生物标志物进行精准的患者富集，设计精巧的、高成功率的PoC研究，以创造关键的估值拐点。退出规划：明确自身是成为独立公司，还是在临床关键阶段被并购，并据此规划资金、团队和合作关系。相关阅读：疼痛领域药物研发进展（2025年Q3）帕金森药物研发进展（2025年7月至今）本文合作商mAbxience简介： mAbxience是一家总部位于西班牙马德里、拥有超十年经验的全球化垂直整合型生物科技企业，以“让全球所有人获得高质量药物，助力人们更好生活”为愿景与使命，核心业务涵盖生物制剂的研发制造及商业阶段CDMO服务，拥有西班牙莱昂及阿根廷加林2个符合先进GMP标准的生产基地（拥有多个单次性生物反应器，最大哺乳动物细胞培养产能达50000L），采用B2B模式与30多家合作伙伴构建网络，业务遍及100多个市场。选择mAbxience的核心优势：其符合国际标准的端到端开发与生产能力及全球化的合规与商业网络，对于拥有创新生物药资产的中国企业，mAbxience 可提供从细胞系开发、工艺优化、到符合美国FDA、欧盟EMA、日本PMDA等严苛法规要求的商业化生产（拥有多个国际GMP认证生产基地）的全链条服务，能显著提升产品价值，加速其通过海外监管审批。同时，公司已通过30多个全球合作伙伴，在100多个市场拥有成熟的商业化经验，可直接协助中国企业进行产品注册，上市后的本地化生产与供应，有效解决授权出海后常见的供应链落地与区域法规适配等核心挑战。通过携手mAbxience，中国药企不仅能以更低风险、更高效率实现“授权出海”，更能借助其强大的全球网络与生产体系，确保产品在国际市场的持续、稳定供应，最终实现商业价值的最大化。合作沟通请联系：电话18621931692 微信号：yj522225 邮箱：yjtang69@hotmail.com 关于Target Tracker 小程序：还在为追踪药物靶点研究进展而烦恼？试试 Target Tracker 小程序！用户只需简单几步设定关注的药物靶点，就能一键获取最新的基础研究论文列表，前沿动态一手掌握，研究进展轻松追踪，为科研之路精准导航，开启高效科研新体验。可以通过Target Tracker小程序高效完成以下功能：热点追踪：添加热点，获得及时论文更新便捷搜索：定制搜索，提高论文搜索精度 Ai助力：快速了解一篇论文核心内容

基因疗法上市批准并购引进/卖出

2026-02-03

·BioSpace

Lobe Sciences Reports First Quarter 2026 Results and Highlights

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter. "During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D expenditures increasing to just under $1 million as we advanced our core programs through Cynaptec Pharmaceuticals, Inc.," said Dr. Fred Sancilio, CEO of Lobe Sciences Ltd. "This progress reflects our transformative approach to drug development of next-generation serotonergic agents, combining our advanced pharmaceutical development expertise, focused subsidiary-level execution with centralized scientific and regulatory core competencies. Importantly, this increased level of activity was achieved alongside improved operating efficiency, underscoring the benefits of our shared services model. We believe this disciplined and scalable approach positions the Company to continue advancing development initiatives while maintaining a strong financial foundation". First Quarter 2026 Financial Highlights Cash totaled $5,991,614 as of November 30, 2025. Short-term investments totaled $1,025,098 as of November 30, 2025. Net working capital totaled $4,047,891 as of November 30, 2025. Research and development expenses totaled $982,087 for the quarter ended November 30, 2025, compared to $7,551 for the same period in the prior year. The increase reflects expenditures related to advancing L-130 (Psilocin Mucate) through preclinical studies and regulatory activities supporting proof-of-concept and investigational new drug filings. Cash flows used in operating activities were $579,006 for the quarter ended November 30, 2025, compared to $243,068 for the same period in the prior year. Net loss was $1,305,827 for the quarter ending November 30, 2025, compared to $800,634 for the same period last year. Operational Highlights During the quarter, Lobe continued to execute on its development strategy, with the majority of research and development expenditures incurred through Cynaptec Pharmaceuticals, Inc., the Company's subsidiary advancing L-130 (Psilocin Mucate). During Q1:2026, Lobe initiated and advanced preclinical, clinical, and regulatory activities, progressing the program in accordance with its development plan. The Company maintained a fiscally conservative approach throughout the quarter, implementing tight controls over the use of cash while increasing development activity. In parallel, Lobe strengthened its development capabilities by adding additional scientific resources to support the advancement of its research and development efforts as programs move toward Phase 1 and Phase 2 clinical activities. Product Development Overview Lobe is advancing two strategic development programs through its subsidiaries: Cynaptec Pharmaceuticals, Inc. (64% owned by Lobe) - L-130 for chronic cluster headache (lead program) and opioid use disorder, with other indications under strategic review. Altemia, Inc. - S-100, an early-stage drug product candidate for sickle cell disease. In addition to these two ongoing programs, the Company continues to evaluate other strategic opportunities consistent with its business strategy. Cynaptec Pharmaceuticals, Inc.: L-130 - A CNS Therapeutic L-130 is a proprietary, orally administered compound engineered as a stabilized derivative of psilocin, the pharmacologically active metabolite of psilocybin. The formulation is designed to improve stability and systemic exposure, with the objective of supporting consistent therapeutic performance. Psilocin has demonstrated potential utility across a range of neurological disorders. L-130 is being developed initially for the treatment of chronic cluster headache, a debilitating neurological condition for which current therapeutic options remain limited. As previously disclosed in the Company's Management's Discussion and Analysis, a Phase 1a clinical study in healthy volunteers, together with a comprehensive body of supporting preclinical studies, has been completed outside of the United States in accordance with applicable regulatory and ethical standards. The Company continues to advance its development and partnering strategy in alignment with guidance received from the U.S. Food and Drug Administration through its Pre-IND interactions and through its regulatory network. Altemia, Inc.: S-100 - Sickle Cell Disease Drug Product Candidate During the quarter, Lobe also focused on its sickle cell disease program, S-100 , an early-stage therapeutic candidate intended to address core disease mechanisms. S-100 utilizes a proprietary drug delivery approach and consists of a multi-component, polyunsaturated lipid-based formulation, primarily comprising of triglyceride esters of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), together with a patented absorption enhancing blend of excipients. In addition, during the quarter the Company continued limited preliminary commercialization activities related to a proprietary medical food designed to address nutritional deficiencies commonly observed in patients with sickle cell disease. These activities remain focused on evaluating potential pathways for third-party reimbursement specifically in the State of Georgia. There can be no assurance that reimbursement approval will be obtained or that commercialization efforts will be successful. Should reimbursement not be achieved, the Company may pursue alternative strategies or elect to discontinue further commercialization activities. Capital and Potential Value-Creation Strategy During the quarter, the Company continued to execute its value creation strategy focused on advancing and realizing the intrinsic value of its existing research and development assets, while selectively evaluating additional opportunities aligned with its business objectives. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE. About Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Altemia, Inc. About Cynaptec Pharmaceuticals, Inc . Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe. About L-130 (psilocin mucate) L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrugpsilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130 stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications. For Further Information Dr. Frederick D. Sancilio Chief Executive Officer Lobe Sciences Ltd. Email: info@lobesciences.com Phone: +1 (949) 505-5623 Website: Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company's belief that its strengthened working capital position will reduce liquidity risk and enhance the Company's ability to execute on its business development initiatives; the Company's belief that its operational and financial stabilization program will position the Company to pursue value-accretive transactions and financing alternatives aligned with shareholder interests; the Company's belief that L-130 will have therapeutic use at sub-hallucinogenic doses and that in addition to the treatment of Chronic Cluster Headaches, L-130 may have additional therapeutic uses; the Company's intention to evaluate other strategic opportunities consistent with its business strategy; the Company's expectation that it will further strengthen its corporate infrastructure and advance its core development programs through disciplined milestone execution are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: a strengthened working capital position will reduce liquidity risk and enhance the Company's ability to execute on its business development initiatives; the Company's operational and financial stabilization program will position the Company to pursue value-accretive transactions and financing alternatives aligned with shareholder interests; L-130 will have therapeutic use at sub-hallucinogenic doses and that in addition to the treatment of Chronic Cluster Headaches, L-130 may have additional therapeutic uses; the Company will have the financial and operational resources to evaluate other strategic opportunities consistent with its business strategy; the Company will be able to further strengthen its corporate infrastructure and achieve its business milestones on the timelines anticipated, among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: a strengthened working capital position will not reduce liquidity risk or enhance the Company's ability to execute on its business development initiatives; the Company's operational and financial stabilization program will be insufficient to allow the Company to pursue value-accretive transactions and financing alternatives aligned with shareholder interests; the Company may not have the financial and operational resources to evaluate other strategic opportunities consistent with its business strategy; L-130 fails to demonstrate therapeutic use at sub-hallucinogenic doses, fails to effectively treat Chronic Cluster Headaches or demonstrate other therapeutic uses; the Company will have the financial and operational resources to evaluate other strategic opportunities consistent with its business strategy; the Company will be unable to further strengthen its corporate infrastructure or achieve its business milestones or do so on the timelines anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. SOURCE: Lobe Sciences Ltd. View the original press release on ACCESS Newswire

财报临床1期临床2期

100 项与裸盖菇素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	裸盖菇素	-	DB11664

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	临床3期	美国	Usona Institute	2024-03-13
难治性抑郁症	临床3期	美国	Compass Pathways Plc	2023-01-19
腰痛	临床2期	美国	Yale University	2026-06-01
周围神经系统疾病	临床2期	美国	The University of Texas MD Anderson Cancer Center	2026-05-04
口吃	临床2期	美国	NYU Langone Health	2026-01-15
乳腺癌	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
子宫内膜癌	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
肾肿瘤	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
皮肤黑色素瘤	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
情绪障碍	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04950608 (PATH, CTgov)	临床2期	疾病进展 \| 晚期癌症	15	Psilocybin	鹽構鹹鏇膚糧範淵廠顧 = 範蓋憲鬱窪壓構鹹觸夢齋鏇壓構壓構蓋獵淵製 (窪選範襯夢壓構醖鹹築, 艱遞願鏇鏇糧獵繭遞觸 ~ 齋願觸廠築繭鬱網製淵) 更多	-	2025-09-02
NCT04424225 (CTgov)	临床1期	致幻 \| 知觉障碍 \| 视觉抑制	10	Psilocybin (Psilocybin)	獵壓鏇構製鹹構範鏇遞(艱醖網廠積夢築築糧齋) = 鏇鬱構餘齋餘襯網鬱獵願願夢構壓構窪壓醖鑰 (齋壓壓壓築鏇夢簾糧壓, .11731) 更多	-	2025-06-27
NCT04424225 (CTgov)	临床1期	致幻 \| 知觉障碍 \| 视觉抑制	10	Niacin (Niacin)	獵壓鏇構製鹹構範鏇遞(艱醖網廠積夢築築糧齋) = 鹹憲衊蓋範築齋獵艱獵願願夢構壓構窪壓醖鑰 (齋壓壓壓築鏇夢簾糧壓, .04398) 更多	-	2025-06-27
NCT05312151 (CTgov)	临床2期	创伤后应激障碍	22	Psilocybin	選醖憲淵簾獵遞襯構艱 = 鬱淵窪鏇窪網鹽觸簾顧鹹鹽觸餘蓋網夢願積壓 (艱鹹構製繭衊觸願網選, 鬱蓋憲選鑰廠選鑰積艱 ~ 膚觸獵廠簾觸廠膚顧繭) 更多	-	2025-06-13
NCT05847686 (CTgov)	临床1/2期	转移性肿瘤 \| 转移性实体瘤 \| 血液肿瘤 ... 更多	55	Counseling+Psilocybin	鏇獵醖製構製選範蓋膚 = 鏇窪鑰窪夢餘艱壓簾艱願鏇淵淵願鏇糧鑰糧廠 (醖醖遞艱醖蓋夢蓋選窪, 顧醖繭簾艱鏇壓構鏇鑰 ~ 襯齋膚醖齋襯齋憲遞糧) 更多	-	2025-04-30
NCT05128162 (CTgov)	临床2期	纤维肌痛	17	Psilocybin	製構醖獵憲鏇製膚願糧(範齋願夢淵壓醖繭積繭) = 製鏇衊糧衊鬱壓膚鏇鹹鑰襯願淵窪簾齋鑰鹽艱 (範願築簾襯鏇選遞夢憲, 壓築鹹餘餘廠觸網餘鬱 ~ 構選選淵廠顧範積獵製) 更多	-	2025-04-16
NCT04141501 (Pubmed \| EClinicalMedicine)	临床2期	酒精使用障碍	37	Psilocybin (25 mg)	襯構鏇衊鹽廠艱壓鹹醖(艱艱夢艱餘艱鏇膚鹹繭) = 窪鏇鏇築艱鹽蓋艱顧鬱糧憲艱簾積夢積襯膚廠 (鏇壓網積繭鑰簾鹽憲鹹, 14.31 ~ 19.29) 更多	不佳	2025-04-01
NCT04141501 (Pubmed \| EClinicalMedicine)	临床2期	酒精使用障碍	37	Placebo (mannitol)	襯構鏇衊鹽廠艱壓鹹醖(艱艱夢艱餘艱鏇膚鹹繭) = 齋觸廠醖齋糧製襯積遞糧憲艱簾積夢積襯膚廠 (鏇壓網積繭鑰簾鹽憲鹹, 10.97 ~ 16.63) 更多	不佳	2025-04-01
NCT05163496 (CTgov)	临床3期	新冠肺炎后遗症 \| 职业倦怠 \| 创伤后应激障碍	30	Psilocybin (Psilocybin Arm)	衊餘醖衊築構蓋廠廠構(醖淵醖積艱簾積鏇窪衊) = 憲鬱壓範廠醖觸鑰淵獵築鹽簾鹽蓋範構壓顧廠 (構憲艱鹹網醖衊艱膚鹹, 7.84) 更多	-	2025-03-18
NCT05163496 (CTgov)	临床3期	新冠肺炎后遗症 \| 职业倦怠 \| 创伤后应激障碍	30	Active placebo (Placebo)	衊餘醖衊築構蓋廠廠構(醖淵醖積艱簾積鏇窪衊) = 願製遞觸膚鑰蓋壓網遞築鹽簾鹽蓋範構壓顧廠 (構憲艱鹹網醖衊艱膚鹹, 7.32) 更多	-	2025-03-18
NCT04718792 (Company_Website \| Pubmed) 人工标引	临床2期	酒精使用障碍	10	PEX010	鹹艱觸顧窪顧壓襯遞衊(鹹願網衊簾餘壓構構壓) = 鑰觸築獵範壓製醖夢蓋範繭廠衊鬱憲網網糧觸 (願遞蓋鹽顧製憲鹹窪淵, −61.1 ~ −13.9) 更多	积极	2025-03-17
NCT04433858 (Pubmed \| J Affect Disord)	临床2期	难治性抑郁症	15	Psilocybin 25 mg	築鹽蓋窪築願餘鹽醖膚(網窪壓願築鬱觸獵餘衊) = 齋願遞鑰壓製艱餘齋醖艱顧窪醖鹹簾選鏇襯簾 (鹹遞鏇壓淵遞鹽觸夢糧 ) 更多	积极	2025-01-01
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	临床2期	重度抑郁症	59	Psilocybin + Placebo (Psilocybin)	範鬱鹽鬱壓遞齋顧鹹鹽(齋築簾醖餘夢醖網鏇積) = 鬱衊鬱蓋網窪鏇鏇膚築築選鬱顧遞獵餘淵憲願 (觸衊願選觸鹹鏇廠製廠, 0.45) 更多	-	2024-10-24
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	临床2期	重度抑郁症	59	Escitalopram+Psilocybin (Escitalopram)	範鬱鹽鬱壓遞齋顧鹹鹽(齋築簾醖餘夢醖網鏇積) = 網憲選築壓衊襯積襯憲築選鬱顧遞獵餘淵憲願 (觸衊願選觸鹹鏇廠製廠, 0.62) 更多	-	2024-10-24